ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)
ARS Pharmaceuticals (SPRY) posted Finished Goods of $7.3 million for Q1 2025, up 39.49% sequentially from $5.2 million in Q4 2024.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025) Analysis & Trends
ARS Pharmaceuticals has reported Finished Goods for 2 years, with the latest figure at $7.3 million in Q1 2025.
- Quarterly Finished Goods changed N/A year-over-year to $7.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $7.3 million (changed N/A YoY) and the FY2024 annual result came in at $5.2 million, changed N/A from the prior year.
- Finished Goods climbed to $7.3 million in Q1 2025 per SPRY's latest filing, from $5.2 million in the prior quarter.
- Over five years, Finished Goods peaked at $7.3 million in Q1 2025 and troughed at $5.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn |